Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 11/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19582603 | 0.83 | CYP46A1 (0.52) | CYP46A1MAPTNOTUMPDK2FFAR4 | |
| SCHEMBL29417787 | 0.83 | CYP46A1 (0.52) | CYP46A1MAPTNOTUMPDK2FFAR4 | |
| SCHEMBL16994767 | 0.81 | CYP46A1 (0.52) | CYP46A1MAPTKDM4EHSD17B10MEN1 | |
| SCHEMBL19386349 | 0.81 | NOTUM (0.56) | MAPTKDM4EHSD17B10NOTUMGAA | |
| SCHEMBL17452148 | 0.80 | CYP46A1 (0.51) | CYP46A1KDM4EHSD17B10MEN1USP2 | |
| SCHEMBL19601721 | 0.80 | MAPT (0.57) | MAPTMEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL22839753 | 0.80 | MAPT (0.43) | MAPTKDM4EHSD17B10MEN1USP2 | |
| SCHEMBL20018697 | 0.79 | MAPT (0.49) | MAPTKDM4EHSD17B10MEN1USP2 | |
| SCHEMBL19386350 | 0.78 | MAPT (0.48) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL2428447 | 0.76 | PIM1 (0.45) | MAPTKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, ACSL6 | CYP46A1 353/4885MAPT 4174/4885KDM4E 2798/4885 |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | CYP46A1 353/4885MAPT 4174/4885KDM4E 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.